Saturday, September 30, 2017 11:24:02 AM
I invite the rest of the board to assume this guy is PN and let him know what you think.
Just in case you are part of the 90% who don't know anything, let me explain:
Cell walls are semi-permeable lipid membranes that allow certain molecules to pass into the cell, such as glucose for metabolism or amino acids for protein synthesis. BPTH uses liposomes because the outer lipid layer is compatible with the lipid cell wall allowing the contents of the liposome to pass through the cell wall. BPTH is not the first or only company to use this method, but they are first to create a liposomal delivery system that has a neutral charge. Past efforts to deliver antisense therapies using liposomes failed because they were positively or negatively charged, which caused toxic side effects in patients. BPTH solved this problem (or more accurately MD Anderson solved this problem and then licensed the tech to BPTH).
The high uptake levels and no toxicity makes BPTH's delivery system very exciting and opens up many applications even beyond cancer therapy. Without a neutrally charged liposomal delivery system, other companies will not be able to replicate BPTH's technology.
Ionis Pharm. uses antisense technology but struggles with toxic side effects. Despite the toxicity, they have partnerships with major pharma companies and a much higher market cap than BPTH.
Comparing Ionis to BPTH, should lead one to the conclusion that BPTH has the more promising antisense technology, but the market disagrees. The science is on our side. So what is wrong? Oh yeah, BPTH is poorly managed.
Despite weak management we continue to hold our shares and even buy more at opportune times, because we understand the disruptive nature of this technology and the promise of better, safer, more effective treatments for those suffering from cancer and other diseases. I hope a partnership with a stronger company can be made soon so BPTH's technology might actually see the light of day.
Recent BPTH News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/17/2024 12:00:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/17/2024 04:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:18:17 AM
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/11/2024 09:30:47 PM
- Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/05/2024 09:46:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:20:35 PM
- Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:10:12 AM
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:10:23 PM
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress • GlobeNewswire Inc. • 05/24/2024 11:00:00 AM
- Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- U.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices Drop • IH Market News • 05/15/2024 11:50:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:10:29 AM
- Bio-Path Holdings Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:10:34 PM
- Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/19/2024 04:14:04 PM
- Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/18/2024 05:57:59 PM
- Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Bio-Path Holdings Expands Global Patent Portfolio • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Bio-Path Holdings Provides 2024 Clinical and Operational Update • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:00:34 AM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM